clinical trial · NCT07118709
A Study of KC1086 in Patients With Advanced Solid Tumors
Beijing Konruns Pharmaceutical Co., Ltd.·phase1·not yet recruiting·n = 66
Advanced Solid Tumors CancerKC1086
brief summary
The purpose of this study is to evaluate the safety，tolerability, pharmacokinetics, and preliminary efficacy of KC1086 in participants with advanced recurrent or metastatic solid tumors. The trial will be divided into two parts: dose-escalation phase and dose-expansion phase.
started
Aug 1, 2025
primary completion
Aug 1, 2028
completion
Dec 1, 2028
last updated
Aug 12, 2025
official title
A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Preliminary Efficacy of KC1086 in the Patients With Advanced Recurrent or Metastatic Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol